Xtandi 40 MG tablet 120S
Ended Awarded
- Contract number
- SPE2DB25FEQEA
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,170
Award facts
- Contract value 100% obligated
- $4,169.59 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 40 mg tablets (120-count units) on September 24, 2025, with an ultimate completion date of September 25, 2025. This firm fixed-price delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at approximately $500 million and valid through November 2026. The award involves no set-aside designation, allowing the woman-owned small business to compete openly in the federal procurement marketplace. Xtandi is a prescription oncology medication used in the treatment of advanced prostate cancer, reflecting the DLA's ongoing pharmaceutical supply needs across military health facilities.
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, serves as the prime contractor. The company has been registered in the System for Award Management (SAM.gov) since 2001 and maintains an established track record of supplying branded and generic prescription drugs, biologics, and medical consumables to Department of Defense healthcare sites nationwide. Through its IDC with the DLA, DMS Pharmaceutical Group has demonstrated capability to fulfill specialized pharmaceutical requirements, including high-cost oncology treatments such as Xtandi, supporting the military health system's patient care needs.
Quick answers
Who was awarded contract SPE2DB25FEQEA?
SPE2DB25FEQEA was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 24, 2025.
How much is contract SPE2DB25FEQEA worth?
The government has obligated $4,170 on SPE2DB25FEQEA.
Is contract SPE2DB25FEQEA an order under another contract?
Yes. SPE2DB25FEQEA is a delivery order under SPE2DB24D9113, an indefinite delivery contract.
Was contract SPE2DB25FEQEA competed?
The extent of competition for SPE2DB25FEQEA was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award